Institut National De La Sante Et De La Recherche Medicale

Universitè De Montpellier

Institut Regional Du Cancer De Montpellier

Oribase Pharma

Institut Regional Du Cancer De Montpellier-val D'aurelle

Biomunex Pharmaceuticals

Gamamabs Pharma Sa

Institut Regional Du Cancer De Montpellier (icm)

Gamamabs Pharma

Centre Val D'aurelle—paul Lamarque

Inserm (institut National De La Sante Et De La Recherche Medicale)

Inserm

Université De Montpellier I

Université De Montpellier 1

Christel Larbouret

Andre Pelegrin

Thierry Chardes

Bruno Robert

André Pelegrin

Bénédicte Fauvel

Nadège Gaborit

Olivier Dubreuil

Christian Larroque

Gwenael Cheve

Yassamine Lazrek

Wilhem Leconet

Aziz Yasri

Stephen D Gillies

Jean-Marc Barret

Pierre Martineau

Philippe Mondon

Abdelhakim Kharrat

Khalil Bouayadi

Gwénaël Cheve

Jean-François Prost

Marie-Alix Poul

Olivier Leger

David Azria

Nadege A Gaborit

Stéphane Degove

Pierre-emmanuel Gerard

Thierry Chardès

Eugene Zhukovsky

Jean-Francois Prost

Stephane Degove

Nadège A Gaborit

The present disclosure relates to bispecific antibodies targeting EGFR and HER2, and methods for the production of these antibodies. The bispecific antibodies consist of one complete antibody on which two VH-VL chains are attached via a linker to each NH terminal region of both VH chains of the antibody. The bispecific antibodies constructed use the amino acid sequences of the heavy chain (VH) and the light chain (VL) variable regions of two monoclonal antibodies targeting EGFR and HER2, namely cetuximab and trastuzumab, respectively.

Bispecific antibodies targeting EGFR and HER2

The present disclosure relates to a neuregulin non competitive allosteric anti-human-HER3 antibody having a human constant region; and less than 65% of the glycan structures carried by the glycosylation site of the antibody comprises a fucose molecule. The antibody is characterized by its variable sequences.

Anti-human-HER3 antibodies and uses thereof

The present disclosure provides human monoclonal antibodies and antibody-drug conjugates against AXL and their use for the treatment of cancer.

Human monoclonal antibodies against AXL

The present disclosure relates to neuregulin (NRG)-non competitive allosteric anti-human-HER3 antibodies and uses thereof in diagnostic and therapeutic methods.

Neuregulin allosteric anti-HER3 antibody

The invention relates to the combined use of anti-EGFR antibodies and anti-Her2 antibodies for the treatment of cancer, especially suitable for cancer expressing high levels of the EGFR type and low levels of HER2. The invention refers in particular monoclonal antibody 'trastuzumab' (HERCEPTIN&#xae;) directed against the HER2 receptors the efficacy of which can be significantly increased in vivo when combined with monoclonal antibody 'matuzumab' (hmAB 425, EMD 72000) directed against EGF receptors. The combination treatment is suitable for patients suffering from cancer having said receptor profile, preferably pancreatic cancer.

Combination therapy using anti-EGFR and anti-HER2 antibodies

The present invention relates to anti-Axl antibodies and uses thereof in diagnostic and therapeutic methods. More particularly, the present invention relates to a monoclonal antibody having specificity for Axl comprising an heavy chain variable region comprising SEQ ID NO:2 in the H-CDR1 region, SEQ ID NO:3 in the H-CDR2 region and SEQ ID NO:4 in the H-CDR3 region; and a light chain variable region comprising SEQ ID NO: 6 in the L-CDR1 region, SEQ ID NO:7 in the L-CDR2 region and SEQ ID NO:8 in the L-CDR3 region. Said monoclonal antibody binds to the extracellular domain of Axl via, SEQ ID NO:9 and SEQ ID NO: 10.

Anti-Axl antibodies and uses thereof

The invention relates to antibodies against HER3 and their use in the treatment of cancer.

Antibodies against HER3

The present invention relates to anti-Axl antibodies and uses thereof in diagnostic and therapeutic methods. More particularly, the present invention relates to a monoclonal antibody having specificity for Axl comprising an heavy chain variable region comprising SEQ ID NO:2 in the H-CDR1 region, SEQ ID NO:3 in the H-CDR2 region and SEQ ID NO:4 in the H-CDR3 region; and a light chain variable region comprising SEQ ID NO: 6 in the L-CDR1 region, SEQ ID NO:7 in the L-CDR2 region and SEQ ID NO:8 in the L-CDR3 region. Said monoclonal antibody binds to the extracellular domain of Axl via, SEQ ID NO:9, SEQ ID NO: 10 and SEQ ID NO: 11.

The present invention provides for isolated anti-human-HER3 antibodies or fragments thereof. More particularly the present invention provides an isolated monoclonal antibody that specifically binds to the extracellular domain of HER-3 and competes for binding to the extracellular domain of human HER-3 with the antibody produced obtainable from hybridoma deposited as CNCM-I-4486. The antibodies described in the present invention are useful for the treatment of cancer.

Anti-human HER3 antibodies and uses thereof

Growing community of inventors

Montpellier, France

Christel Larbouret